Hospital Universitari Dexeus Grupo Quironsalud — Clinical Trial Site

141 Registered trials

58 Currently recruiting

Organisation

Hospital Universitari Dexeus Grupo Quironsalud

Location

Barcelona, Spain

Identifier

ORG-100030777

Address

Calle De Sabino Arana 5-19, 08028, Spain

Departments

-
1601:Oncología
Allergy
Cirugía Ortopédica y Traumatología
Consulta Oncología -1.1
Department of Gynecology and Obstetrics
Department of Reproductive Medicine
ESP007: Oncología Médica
Gynaecology
Gynecology and Obstetrics
Haematology
Hematología
Instituto Oncológico Dr Rosell
Medica Oncology
Medical Oncology
Medical Oncology Service
N/A
Neonatology department
Neurología
Obstetricia
Obstetrics and Gynecology
Onclogy
Oncología
Oncología Médica
Oncology
Oncology Department
Oncology Service
Ophtalmology
Servicio de Oncología
Servicio de Oncología - Instituto Oncológico Dr. Rosell (IOR)
Servicio de Oncologia Medica

Clinical trials at this site (141)

Search interface

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 "Inoperable or Metastatic Hormone Receptor-Positive, HE 5 2022-01-18
DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended

2023-505210-18-00 Early stage HER2-positive breast cancer (T stage >= T3, 5 2021-12-17
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Breast Cancer 5 2021-09-30
Efficacy and Safety Comparison of Niraparib to Placebo in Participants with HER2 Negative BRCAmut or Triple-Negative Breast Cancer with Mole… Ended

2023-504454-35-00 Neoplasms, Breast 5 2021-06-22
Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended

2023-508738-32-00 Previously untreated and histologically confirmed HER2- 4 2021-06-16
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
"Study of chemotherapy vs immunotherapy for patients with lung cancer bounded in the thorax and completely resected" Ended

2024-513730-38-00 Resectable Non-small cell lung cancer 5 2021-01-13
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 5 2020-12-23
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended

2023-506576-27-00 EGFR-mutated locally advanced or metastatic Non Small C 5 2020-09-30
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch… Ended

2022-502354-14-00 Completely resected Stage IIb/c melanoma 5 2019-10-28
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Ended

2023-508864-31-00 Achondroplasia 5 2019-04-03
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell … Ended

2023-507902-15-00 Non-Small Cell Lung Cancer 4 2019-03-26
A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended

2024-510985-17-00 First Line Treatment in Subjects with Claudin 18.2 (CLD 4 2019-03-14
Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors Ended

2023-507564-39-00 Patients with Advanced Solid Tumors 1 2019-03-11
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Ended

2023-503812-34-00 Locally Advanced or Metastatic Disease in Solid Tumors 4 2019-02-13
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF DEBIO 0123 AND SACITUZUMAB GOVITECAN IN TNBC OR HR+/HER2- ADVANCED/ METASTATIC BREAST C… Halted

2024-516322-60-00 TRIPLE-NEGATIVE OR HR+/HER2– ADVANCED/METASTATIC BREAST 9 2025-01-17
Phase Ib/II trial of the combination of atezolizumab with dendritic cell vaccination as maintenance treatment in patients with extensive sta… Ended

2024-518636-36-00 Lung Cancer 8 2024-10-10
ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended

2023-509716-29-00 Solid Tumors, Colorectal Cancer and Breast Cancer 9 2024-09-23
The impact of the intensity of ovarian stimulation on embryo quality in predicted suboptimal responders. A randomized controlled trial. Ended

2024-514322-23-00 infertility 6 2024-09-09
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian … Ended

2023-508149-42-00 Infertility in women undergoing assisted reproductive t 3 2024-07-16
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation Ended

2023-507630-25-00 Infertility in women undergoing assisted reproductive t 3 2024-06-14